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Abstract
Idiopathic pulmonary fibrosis (IPF), the prototype of interstitial lung diseases, has the worst prognosis and is the
only interstitial lung disease for which approved pharmacological treatments are available. Despite being considered a
rare disease, IPF patients pose major challenges to both physicians and healthcare systems. It is estimated
that a large number of IPF patients reside in BRIC countries (Brazil, Russia, India, and China) given their overall
total population of approximately 3 billion inhabitants. Nevertheless, the limited availability of chest imaging in BRIC
countries is considered a chief obstacle to diagnosis, since high-resolution computed tomography of the chest is the
key diagnostic test for IPF. Further, obtaining reliable lung function tests and providing treatment access is difficult in
the more rural areas of these countries. However, IPF might represent an opportunity for BRIC countries: the
exponentially increasing demand for the enrollment of IPF patients in clinical trials of new drugs is predicted to face a
shortage of patients – BRIC countries may thus play a crucial role in advancing towards a cure for IPF.
Keywords: BRIC countries, High-resolution computed tomography, Idiopathic pulmonary fibrosis, Nintedanib,
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Introduction
Luca Richeldi (Fig. 1)
Idiopathic pulmonary fibrosis (IPF) is the prototype of
interstitial lung diseases (ILDs), a group of pulmonary
diseases also referred to as “rare lung diseases”. A rare
disease is defined by the European Union as one that
affects less than 5 in 10,000 of the general population; as
a consequence, a single rare disease may affect only a
handful of patients, whereas another may affect as many
as 250,000. Therefore, the concept of “rare” needs to be
further defined in order to more accurately address dis-
eases and their interventions. Diseases (both common
and rare) do not present boundaries or geographic pref-
erences; this is particularly true for diseases, such as IPF,
for which risk factors linked to a particular racial back-
ground or a specific, defined geographic area or environ-
ment have not been identified to date. Thus, it is likely
that the burden of disease will be concentrated in the
most densely populated regions of the globe. In this con-
text, BRIC countries (Brazil, Russia, India, and China),
with an estimated 2.9 billion inhabitants overall, may
comprise 1 million cases of a rare disease, thus easily
representing a major medical need.
Defining the exact epidemiology of a rare disease is a
challenge: IPF is not an exception to this rule. Different
data collection approaches have been applied in measur-
ing the incidence and prevalence of IPF, and the findings
of these studies vary widely [1]. A recent study using a
sensitive algorithm in the United States found that the
incidence and prevalence of IPF, corrected for positive
predictive value, were 14.6 per 100,000 person-years and
58.7 per 100,000 persons, respectively [2]. These esti-
mates indicate that, in a large, populated area like the
BRIC region, there may be approximately 2 million per-
sons living with IPF. This poses unique challenges to
healthcare systems, particularly in an era when effective
and safe drugs for IPF are finally available [3]. Thus, the
exploration, using first-hand experience, of the chal-
lenges and opportunities related to the diagnosis and
management of patients with IPF in BRIC countries is of
particular relevance. Further, issues such as the availabil-
ity of high-resolution computed tomography (HRCT)
and spirometry or the existence of a multidisciplinary
diagnostic environment, which would not present a
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problem in high-income countries and yet are crucially
relevant to the BRIC country context, must be ad-
dressed. On the other hand, the rapidly increasing de-
mand for the enrollment of IPF patients in clinical trials
of new drugs could lead to BRIC countries becoming a
major source of trial participants. This opportunity has
been previously explored in a recent phase III trial [4].
In order to ensure that IPF patients obtain an accurate
and prompt diagnosis and appropriate access to treat-
ment, field experts, healthcare agencies, and funding
bodies must join forces in order to identify sensible and
feasible solutions.
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IPF in Brazil
Adalberto Sperb Rubin (Fig. 2)
IPF is the most commonly diagnosed ILD in Brazil.
Despite epidemiological studies on the Brazilian popu-
lation being rare [5], IPF has received special atten-
tion from the Brazilian pulmonology community [6].
The Brazilian Society of Pneumology and Tisiology
(Sociedade Brasileira de Pneumologia e Tisiologia, SBPT)
has a very active Interstitial Lung Diseases Committee,
which organizes continuing education programs at na-
tional symposia and congresses. Brazil has six tertiary
referral centers to treat ILDs, and more are being created.
In recent years, Brazil has participated in multicenter
studies developing new treatments for IPF. Many of the
patients involved are still participating in the open phase
of these studies, contributing to a better understanding of
the long-term effects of these new drugs. Substantial
changes to the diagnosis and treatment of IPF, both in
Brazil and worldwide, have been recently implemented.
These changes have led to easier diagnosis, making histo-
logic biopsies less common; on the other hand, studies
have demonstrated that current treatments do not have
the anticipated clinical effectiveness [7].
In Brazil, as in many countries, the initial challenge of
IPF is based on its proper diagnosis, since this process
has significant therapeutic implications. Therefore, IPF,
which has as a histologic substratum of usual interstitial
pneumonia, must be distinguished from other chronic
fibrosing lung diseases as well as from other ILDs.
Indeed, in Brazil, cases of chronic hypersensitivity pneu-
monitis with characteristics very similar to IPF have
been recorded [8]. Therefore, whenever possible, the
diagnostic process should involve a multidisciplinary
Fig. 1 Luca Richeldi is Professor of Respiratory Medicine and Chair
of Interstitial Lung Disease at the University of Southampton, UK. He
is also a member of the editorial board of BMC Medicine and guest
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Management, and New Therapies
Fig. 2 Adalberto Sperb Rubin is Professor of Pulmonary Medicine at
the Federal University of Health Sciences of Porto Alegre. He has a
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group, including a pulmonologist, radiologist, and path-
ologist (when necessary), with experience in ILDs.
For a number of years, we have followed various
international directive agreements and implemented an
anti-inflammatory treatment strategy as part of the man-
agement of IPF. Recent studies performed in a Brazilian
population indicated the possibility that a combination
of corticoids and immunosuppressant drugs had benefi-
cial effects [9]. The PANTHER study [3, 7] tested the
“triple therapy” (steroids, azathioprine, and N-acetyl
cysteine), revealing opposite results to those previously
anticipated. As a result of this evidence, the use of this
therapeutic strategy is contraindicated, and Brazil’s
tertiary referral centers no longer use it.
The relationship between gastroesophageal reflux dis-
ease and IPF has long been under evaluation in Brazil
[10], as in other countries. Studies have shown that pa-
tients receiving anti-reflux treatment, especially proton-
pump inhibitors, may have a better survival. Therefore,
many patients in Brazil are treated in an empirical way
with this medication in order to reduce disease progres-
sion. Nevertheless, despite this course of conduct being
widely used in current practice, better scientific proof of
its effectiveness is required.
As with patients with other chronic lung diseases, IPF
patients are included in pulmonary rehabilitation pro-
grams, and studies have demonstrated an improvement
in various outcomes associated with their quality of life,
with the 6-minute walk test used as one of the markers
of this benefit [11].
Lung transplantation, recommended in cases where
the symptoms are progressive and where functional loss
indicates reduced survival, is one of the few therapeutic
strategies that has a real impact on survival with IPF
[12]. However, this option is limited, especially in Brazil,
where few medical centers can perform a procedure of
such high complexity and given the low number of
organ donors. There are currently two very active cen-
ters with established lung transplantation programs in
Porto Alegre and São Paulo. The Santa Casa of Porto
Alegre Hospital has already performed more than 500
lung transplantations and, currently, more than 50 % of
new transplantation cases are IPF patients.
In 2014, two publications in the New England Journal
of Medicine [13, 14] presented data from multicenter
studies on IPF treatment with nintedanib and pirfeni-
done. Following FDA approval for these drugs, Anvisa –
the Brazilian regulatory body – began the process of
releasing them in Brazil, with these new treatments pre-
dicted to become available in the second half of 2015.
These drugs will have a profound impact on the man-
agement of IPF in Brazil, since no effective therapy is
currently available to treat this population. In 2012,
the SBPT published national directives for managing
ILDs [5]; it has since become clear that the available
therapies have shown little or no clinical evidence of
effectiveness.
As is the case in all BRIC countries, the greatest chal-
lenges lie in the availability of computed tomography
(CT) and the equipment necessary to test lung function
in the less developed parts of the country. Further, Brazil
lacks a large enough number of pathologists and radiolo-
gists with experience in the precise diagnosis of ILDs,
something which is fundamental to managing IPF.
Nevertheless, there has been rising interest for IPF and
its appropriate management within the national medical
community, which, along with the availability of new
therapies and further exchange with other countries,
should lead to an improvement in IPF patient care in
Brazil.
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IPF in Russia
Sergey Avdeev (Fig. 3)
IPF is currently considered by Russian physicians as a
disease that is difficult to diagnose and particularly diffi-
cult to treat [15]. To date, there are no national guide-
lines for the diagnosis and management of IPF in Russia
and there is no unique name for the disease – along
with the term “IPF” [16], the term “idiopathic fibrosing
alveolitis” is also widely used [17]. The majority of IPF
patients are followed up by pulmonologists in large
multidisciplinary hospitals and outpatient centers in
large cities of Russia. Further, the diagnosis of IPF
has improved over the past 10 years due to easier ac-
cessibility to CT and to the increased awareness of
the disease [18].
Epidemiological studies on the prevalence and inci-
dence of IPF in Russia have not been conducted and
therefore only rough estimates based on a survey con-
ducted in Moscow are available [19]. Extrapolation of
data from this survey suggests that the prevalence and
incidence of IPF are approximately 9–11 and 4–6 cases
per 100,000 population, respectively. The median esti-
mated survival of IPF patients from the time of diagnosis
is only 2–3 years. In order to obtain a clearer picture of
the state of IPF in Russia to date, data obtained from a
recently conducted national survey of more than 30
leading expert pulmonologists involved in the manage-
ment of IPF patients [20] is discussed below.
The data indicates that the average number of IPF
patients attending a given participating center over
1 year was 49 (range, 10–150 patients). The participating
centers were large multispecialty hospitals (attended 38 %
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of cases), outpatient centers (28 % of cases), and special-
ized pulmonology centers (50 % of cases). According to
interviewed experts, the average age of patients was more
than 60 years (67 % of responses). IPF patients in Russia
are characterized by male predominance (66 %) with a
high prevalence of smokers (61 %). At the time of initial
diagnosis of IPF, the average level of forced vital capacity
was 50–80 % of predicted values in 78 % of patients and
less than 50 % of predicted values in 22 % of patients. The
usual duration of symptoms before the diagnosis of IPF
was 6–12 months (44 % of responses), 12–18 months
(17 % of responses), or more than 24 months (22 % of re-
sponses; Fig. 4). Most often, patients with suspected IPF
were sent to participating centers by general physicians
(56 %), pulmonologists (22 %), and radiologists (22 %). A
surgical lung biopsy for confirmation of a diagnosis of IPF
was performed, on average, in 20 % of patients (mainly in
young patients and in patients with atypical CT imaging).
According to the experts’ answers, 89 % of the interviewed
experts had the ability to discuss the results of CT scans
with radiologists, 89 % of interviewed pulmonologists had
the ability to discuss the results of lung biopsies with mor-
phologists, and 77 % of participating centers had the pos-
sibility of facilitating a multidisciplinary discussion about
IPF cases.
The primary complaints of IPF patients at the time of
initial diagnosis were dyspnea (100 %), cough (56 %),
weight loss (11 %), and general weakness (5 %). The
initial findings that most frequently revealed IPF were
incidental findings on chest X-ray or chest CT (78 %),
dyspnea (56 %), “velcro” crackles at lung auscultation
(39 %), and cough (28 %). According to the interviewed
experts, the most frequent comorbidities and complica-
tions in IPF patients were gastroesophageal reflux dis-
ease (57 %), cardiovascular disease (54 %), pulmonary
hypertension (38 %), emphysema (33 %), sleep apnea
(14 %), and lung cancer (3 %).
More than 90 % of IPF patients in Russia receive
pharmacological therapy. The most commonly initiated
therapies are oral corticosteroids (56 %), immunosup-
pressants (azathioprine or cyclophosphamide; 11 %), N-
acetylcysteine (83 %), long-term oxygen therapy (89 %),
anti-reflux agents (72 %), and pirfenidone (5 %; Fig. 5). If
oral corticosteroids are prescribed, doses in the majority
of centers are low (10–20 mg of prednisolone daily). Pir-
fenidone and nintedanib are not yet registered in Russia,
and therefore their administration is possible only in pa-
tients who have the opportunity to obtain the drugs
abroad.
A lung transplantation program is being actively devel-
oped in Russia [21]. Patients who have successfully
undergone a lung transplantation include patients with
advanced IPF. However, the main challenges of lung
transplantation for IPF patients, as in many other coun-
tries, are the shortage of donor organs and the relatively
small number of lung transplant centers.
Fig. 4 The mean duration of symptoms in idiopathic pulmonary
fibrosis patients at the time of initial diagnosis
Fig. 3 Sergey Avdeev is Professor of Respiratory Medicine at the
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Finally, most interviewed experts (89 %) reported that
they used, for the management of IPF patients, the joint
recommendations of the American Thoracic Society, the
European Respiratory Society, the Japanese Respiratory
Society, and the Latin American Thoracic Association
(2011), although some also stated that they rely on other
recommendations.
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IPF in India
Zarir F. Udwadia (Fig. 6)
Most pulmonologists in India will admit to seeing a
large number of patients with IPF in their practice and
concede that the number seems to be increasing over
the years. Nevertheless, this statement cannot be backed
up by objective evidence in the form of epidemiological
studies of incidence or prevalence since none are avail-
able. This section will discuss what is known about IPF
in the context of a country of 1.2 billion people and
focus on its distinctive features in the Indian setting.
There has been a recent surge in the recognition of
IPF in India. The initial Indian report of IPF occurred in
1979 by Jindal et al. [22], from the Postgraduate Institute
of Medical Education and Research, the country’s
most esteemed post-graduate medical institution in
Chandigarh. The study reported that almost 46 % of
patients (n = 61) with diffuse parenchymal lung dis-
ease (DPLD) had IPF. A few years later, Mahashur
et al. [23], from another large teaching hospital in
Bombay, reported that IPF accounted for 50 % of
cases in a mixed group of 63 patients with DPLDs;
the advantage of this study was that open lung biop-
sies were performed in the majority of patients. In
1984, a larger study by Sharma et al. [24], from New
Delhi, showed that IPF accounted for 28 % of patients
with ILD. Since then, there have been isolated studies
by Maheshwari et al. [25] and Subhash et al. [26] in
2004, Sen and Udwadia in 2010 [27], and Kundu et al. in
2014 [28], from centers representing all the major regions
in the country, all demonstrating that IPF accounted for
significant numbers of patients with DPLDs in India. The
major findings from these studies are summarized in
Table 1.
Thus, available epidemiological data is limited to a few
studies, all of which were retrospective. Nevertheless,
these studies focused on different parts of India and
showed no regional variations, and they all indicated
that IPF is the most common cause of DPLD, being
more common than other DPLDs such as sarcoidosis,
hypersensitivity pneumonia, and ILD secondary to colla-
gen vascular disease.
Unfortunately, these studies do not provide informa-
tion on the prevalence of IPF. If one extrapolates even
the more conservative prevalence of 10 cases per
Fig. 5 The proportion of physicians who prescribed each of the
specified treatments in patients diagnosed with idiopathic
pulmonary fibrosis
Fig. 6 Zarir F. Udwadia is a consultant pulmonologist at Hinduja
Hospital and Research Centre, Mumbai, India. His research interests
include interstitial lung disease and drug-resistant tuberculosis. He
has written over 100 peer-reviewed articles and authored chapters
in several international textbooks
Table 1 Studies reporting idiopathic pulmonary fibrosis (IPF) in
India
Study authors [ref.] Study population Proportion with
IPF/main findings
Jindal et al. [22] 61with diffuse parenchymal
lung disease (DPLD), 5 years
46 %
Sharma et al. [24] 133 patients with DPLD 28.6 %
Maheshwari et al. [25] 76 patients with IPF Female preponderance
Subhash et al. [26] 97 patients with DPLD 43 %
Sen andUdwadia [27] 274 patients with DPLD,
7 years
43 %
Kundu et al. [28] 92 patients 38 %
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100,000 from Gribbin’s IPF data from the UK [29], this
translates into at least 130,000 potential IPF patients in
India. These numbers, coupled with physicians’ empir-
ical observations of numbers being seemingly on the
rise, indicate that IPF will pose a significant disease
burden. Whether this is a true increase, or represents an
aging Indian population or increased physician aware-
ness coupled with improved availability and quality of
CT scanning, is difficult to determine. Nevertheless, an
important clinical observation is that IPF in India is
generally diagnosed at an advanced stage due to various
reasons, as discussed below.
Overlap with tuberculosis (TB):TB still dominates re-
spiratory medicine in India and there is a tendency to
initially mislabel patients with IPF as TB. These patients
are subjected to long and unfruitful anti-TB drug trials
before the correct diagnosis is finally considered [30].
Whilst the infiltrates produced by TB can rarely be mis-
taken for fibrosis, and despite the fact that as many as
65 % of patients with TB are left with residual fibrosis at
the end of their treatment (Udwadia ZF, Shah H, unpub-
lished data), mislabeling rarer DPLDs as TB requires a
change in mindset which will materialize with better
education of general physicians and internists.
Over reliance on chest radiography:In a resource-
limited setting like India, a chest radiograph is always
the initial, and sometimes only, diagnostic test a patient
from the rural interiors undergoes. Whilst chest radiog-
raphy has a low sensitivity at the best of times, the qual-
ity of some of these radiographs is so poor that IPF is
often never suspected and further work up never
initiated.
Poor HRCT penetrance: The first attempts at HRCT
of the lungs began in centers in Mumbai and Delhi in
1991. The currently installed CT scanner base of 5,000
machines in the country is woefully inadequate to meet
the needs of the population. India’s CT penetrance of
one scanner per million population is much less than
that of most of its BRIC neighbors. In addition, the ma-
jority of scanners (outside of the country’s main metro-
politan areas) are of poor quality and incapable of
imaging at 1-mm slice thickness. Countrywide, there are
only a few radiographers with a special interest in chest
imaging who will provide good quality images and their
interpretation.
Pulmonary function test unavailability:In smaller rural
centers, though spirometry is widely performed, diffu-
sion capacity is seldom available and the 6-minute walk
testing rarely performed.
Surgical biopsies and their interpretation: Although
surgical biopsies are currently less commonly required
in IPF since HRCT scanning has assumed a pivotal pos-
ition in the diagnostic algorithm, on the occasions in
which they do need to be performed, there are very few
surgeons across the country capable of performing
video-assisted surgical biopsies and even fewer lung pa-
thologists capable of interpreting them accurately.
Treatment of IPF in India has followed global trends:
initial treatment revolved around high dose steroids and
was followed by triple therapy with steroids, azathio-
prine, and N-acetyl cysteine; current treatment revolves
around the use of pirfenidone. Interestingly, this novel
anti-fibrotic drug has been available in generic form
through two Indian pharmaceutical companies since
2010, several years before it received European Union
and National Institutes of Health approval. Steroids are
still used freely and in large doses, despite a large body
of evidence suggesting they do more harm than good.
Steroids, if used at all in IPF, must be used with great
caution in the Indian context – the world’s largest dia-
betic (65 million) and TB populations (2.2 million cases)
reside in this country and the potential for harm to these
patients is great. India also has a huge population of
patients with latent TB infection and the risk of activa-
tion of TB in these patients when given steroids for IPF
is high.
Lung transplantation for IPF has yet to make a foot-
hold in this country. The first lung transplantation for
IPF was performed at the Hinduja Hospital as recently
as 2012. This patient survived only 3 months and the
handful of cases subsequently transplanted from a few
other centers across the country have also met limited
success.
IPF in India is widely prevalent but countrywide epi-
demiological studies are needed to map its exact inci-
dence and prevalence. It is often misdiagnosed or
diagnosed late (the previously described “TB effect”) and
is often treated with traditional immunosuppression des-
pite the more widespread availability of pirfenidone.
Thus, centers of excellence where expert pulmonolo-
gists, radiologists, and pathologists can see these patients
in consensus are required. Lung transplantation must
also be expanded with the major hospitals in the larger
cities offering this much needed option to IPF patients.
A nationwide electronic ILD registry has recently been
established and has already enrolled 700 patients from at
least 20 different centers across the country [31]; this
will provide important data and an evidence base for
future research into IPF in India.
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IPF in China
Zuo Jun Xu (Fig. 7)
ILD, also referred to as DPLD, is a heterogeneous
group of diseases that mostly involves the pulmonary in-
terstitium. IPF is a specific form of chronic, progressive
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fibrosing idiopathic interstitial pneumonia [32]. To date,
there have been no nationwide or large-scale prospective
epidemiological studies of the clinical treatment of dif-
ferent types of ILD (including IPF) patients in China.
However, a number of medical centers focus on the
diagnosis and treatment of ILD as a respiratory disease
specialty and follow international standards regarding
the diagnostic procedures and treatment of IPF patients.
In China, the diagnosis and treatment of IPF, as well as
related research, are generally conducted in hospitals af-
filiated with medical schools, namely teaching hospitals.
The highest official guidance institution for ILD in
China is the Interstitial Lung Disease Study Group of
the Chinese Thoracic Society, which is responsible for
the introduction of the latest international consensus
and research progress on ILD to clinicians specialized in
respiratory medicine throughout the country via lectures
and articles, as well as for nationwide clinical research
related to ILD. The classification and naming of idio-
pathic interstitial pneumonias in China strictly follow
the relevant international guidelines.
To date, China has not conducted any national
population-based epidemiological surveys on IPF and,
therefore, no epidemiological data of IPF in the Chinese
population are currently available. Only a few analyses
have been conducted on the diagnosis and treatment
data of hospitalized ILD patients in several local areas
[33–36]. A 2003 study from the Interstitial Lung Disease
Group of the Chinese Thoracic Society revealed that the
10 hospitals surveyed admitted and treated 56 ILD cases
in 1990, accounting for 1.98 % of the yearly hospitalized
cases in the Department of Respiratory Medicine, while
the number rose to 485 ILD cases in 2003, accounting
for 4.66 % of the yearly hospitalized cases [33]. A single-
center study by Li et al. [34] found that a total of 395
ILD patients were admitted from 1990 to 2003; of these,
58 ILD patients (14.7 %) were admitted from 1990 to
1997 and 395 ILD patients (85.3 %) from 1998 to 2003.
The 2008 data from the Chongqing Interstitial Disease
Collaborative Group showed that ILD cases admitted to
the five surveyed teaching hospitals in 2002 accounted
for 2.8 % of all hospitalized cases in the Department of
Respiratory Diseases in that year, with the ratio increas-
ing to 8.3 % in 2006 [35]. A 2012 study by Wei et al.
[36] including 10 hospitals in Tianjin, suggested that
hospitalized ILD cases accounted for 4.5 % of all hospi-
talized cases in the Department of Respiratory Diseases
in 2003, while this ratio increased to 39.5 % in 2009. The
above data revealed that, after accounting for the
changes in the Chinese population [6], the incidence of
ILD in China showed a gradual upward trend after 2000.
This upward trend may be related to improvement in
relevant ILD diagnostic techniques and increased ILD
awareness [32], as well as a possible real increase in ILD
incidence [33].
Two of the studies mentioned above, including 3,568
patients with ILD, found that idiopathic interstitial pneu-
monias were seen in 53 % of patients (1,891 cases), IPF
in 25.1 % (894 cases), connective tissue disease-
associated ILD in 14 % (499 cases), sarcoidosis in 4 %
(144 cases), and extrinsic allergic alveolitis in 3.8 % (100
cases) [33, 36]. A retrospective study by Zhang et al. [37]
analyzed 418 patients with ILD diagnosed by lung biopsy
from 1999 to 2009 in China and showed that idiopathic
interstitial pneumonias were found in 41.9 % of patients.
Of these, 35.4 % (62 cases) were found to be IPF,
followed by unclassifiable interstitial pneumonia (21.7 %;
38 cases), non-specific interstitial pneumonia (19.4 %; 34
cases), and chronic obstructive pulmonary disease
(13.7 %; 24 cases).
The various hospital categories exhibit substantial dif-
ferences in the diagnosis of IPF. At most community- or
county-level hospitals, IPF is often missed or misdiag-
nosed. Many IPF patients are often first mistakenly
diagnosed with pneumonia or chronic obstructive pul-
monary disease. In addition, due to insufficient aware-
ness of ILD, physicians sometimes misdiagnose alveolar
protein deposition disease, certain secondary ILDs, and
certain infectious pneumonias as idiopathic interstitial
pneumonitis and treat these diseases with corticosteroids
Fig. 7 Zuo Jun Xu, is the Chief Physician and a Professor at the
Respiratory Disease Department of Peking Union Medical College
Hospital, Peking Union Medical College and Chinese Academy of
Medical Sciences, and is also the Vice Director of the Interstitial Lung
Disease Group of the Chinese Society of Respiratory Diseases,
Chinese Medical Association. He is a member of the Council of
Beijing Medical Doctor Association as well as a member of the
Standing Committee of the Beijing Association of Traditional
Chinese Medicine and Western Medicine. He has published over 200
scientific papers and participated in the editing of 65 monographs
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with/without immunosuppressive therapy. However, in
hospitals that specialize in the diagnosis and treatment
of ILD, the procedures for IPF diagnosis and treatment
are highly standardized. For patients with pathological
data, the diagnostic guideline is to establish a final diag-
nosis based on discussion among clinical experts, radiol-
ogists, and pathologists who are specialized in ILD. In
hospitals that do not have the capacity for C-reactive
protein diagnosis, physicians sometimes transfer the
related data to teaching hospitals with the appropriate
capabilities for consultation.
Fourteen sites in China participated in the recent
phase III international clinical study using nintedanib for
the treatment of IPF [14]. A total of 153 patients with
ILD were screened, 101 patients were randomly enrolled,
and the overall diagnostic accuracy rate was 66 %.
Among the 25 patients with ILD screened at our center,
24 patients showed HRCT images meeting the IPF diag-
nostic criteria, with a diagnostic accuracy rate of 96 %.
The different diagnostic accuracy rates reflect the gaps
in diagnostic capacities among various hospitals in
China and between China and the international medical
field.
In China, several problems exist in the diagnosis and
treatment process of IPF patients. Firstly, most hospitals
have chest radiologists, but only a few have radiologists
specialized in ILD. The lack of specialized radiologists,
to some extent, results in respiratory disease specialists
having a better understanding of ILD chest imaging than
radiologists, thus weakening the role of radiologists in
the diagnosis of IPF. In addition, chest HRCT examin-
ation is not universal, and many basic primary hospitals
are not able to perform these, which is one of the rea-
sons that many primary hospitals cannot determine a
correct diagnosis of IPF. Second, although some hospi-
tals have pathologists with expertise in ILD, the vast ma-
jority of hospital pathologists in China are general
pathologists, and there are almost no specialized lung
pathologists in the entire country. This problem may
also be shared by most other hospitals outside China.
Finally, because the Chinese healthcare system does not
have an established referral system, most hospitals still
do not have the capacity to systematically manage the
relevant clinical data of outpatients, and the information
of IPF patients who only receive outpatient treatment
cannot be systematically organized/managed.
The majority of ILD treatment centers in China are
able to conform to international standards in terms of
IPF treatment regimens by studying the related litera-
ture, updating treatment programs for IPF patients, and
standardizing the treatment of these patients. Further,
many new drugs can enter the Chinese market in a
timely manner given the increased opening of trade.
With the improvement of basic pharmaceutical research
capacities, China also has several new IPF drugs that
were originally developed domestically, such as pirfeni-
done. In addition, traditional Chinese medicine and ther-
apy are unique to China, and attempts to treat IPF using
these traditional methods, including certain results from
basic and clinical research, suggest that some Chinese
medicines may improve the symptoms and prognosis of
the disease [38–42]. Finally, through the introduction
and further improvement of organ transplantation in
China, as well as national benefits for the medical costs
of organ transplant patients, there have been recent
reports of lung transplantations in ILD patients [43].
However, there are still some shortcomings in IPF pa-
tient care. First, due to deficiencies in the follow-up of
patients in the Chinese healthcare system, the vast ma-
jority of hospitals do not conduct systematic follow-up
of ILD patients. Many IPF patients seek treatment at
multiple hospitals, and therefore their information is
used repeatedly. Second, limited by the realities of new
drug approval in China, many new drugs will take 3–5
years longer to enter the market compared to those in
other countries. Third, although basic research results
have suggested that traditional Chinese medicine can
improve pulmonary fibrosis and has been widely used
for the treatment of IPF in China, the specific mechan-
ism of action and the identities of functional compo-
nents in traditional Chinese medicine remain unclear. In
addition, traditional Chinese medicine treatment re-
quires individualization, and it is very difficult to apply a
single prescription to all patients or to conduct double-
blind studies. Therefore, there have been no large
randomized controlled trials on IPF treatment using
traditional Chinese medicine. Finally, due to the extreme
lack of lung donors and the high cost of organ trans-
plantation, as well as traditional resistance to organ
transplantation in China, only a few IPF patients receive
lung transplants each year.
In summary, ILD incidence has shown a gradual in-
crease in China. Teaching hospitals with ILD treatment
centers or specialized in ILDs are able to keep pace with
the development of international IPF treatments and
standardize the treatment of IPF patients. However,
given the condition of China’s healthcare system, fur-
ther improvements are required for IPF diagnosis and
treatment.
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